ZA948061B - Galanthamine derivatives a process for their preparation and their use as medicaments - Google Patents

Galanthamine derivatives a process for their preparation and their use as medicaments

Info

Publication number
ZA948061B
ZA948061B ZA948061A ZA948061A ZA948061B ZA 948061 B ZA948061 B ZA 948061B ZA 948061 A ZA948061 A ZA 948061A ZA 948061 A ZA948061 A ZA 948061A ZA 948061 B ZA948061 B ZA 948061B
Authority
ZA
South Africa
Prior art keywords
compounds
medicaments
preparation
galanthamine derivatives
galanthamine
Prior art date
Application number
ZA948061A
Other languages
English (en)
Inventor
Raymond W Kosley Jr
Larry Davis
Veronica Taberna
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Publication of ZA948061B publication Critical patent/ZA948061B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA948061A 1993-10-15 1994-10-14 Galanthamine derivatives a process for their preparation and their use as medicaments ZA948061B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/137,444 US6316439B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (1)

Publication Number Publication Date
ZA948061B true ZA948061B (en) 1995-06-06

Family

ID=22477461

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA948061A ZA948061B (en) 1993-10-15 1994-10-14 Galanthamine derivatives a process for their preparation and their use as medicaments

Country Status (23)

Country Link
US (1) US6316439B1 (pt)
EP (1) EP0649846B1 (pt)
JP (1) JP2664343B2 (pt)
KR (1) KR100227957B1 (pt)
CN (1) CN1039910C (pt)
AT (1) ATE211474T1 (pt)
AU (1) AU696170B2 (pt)
CA (1) CA2118172C (pt)
CZ (1) CZ283731B6 (pt)
DE (1) DE69429570T2 (pt)
DK (1) DK0649846T3 (pt)
EG (1) EG20726A (pt)
ES (1) ES2170759T3 (pt)
FI (1) FI108722B (pt)
IL (1) IL111275A (pt)
NO (1) NO307464B1 (pt)
NZ (1) NZ264682A (pt)
PL (1) PL177549B1 (pt)
PT (1) PT649846E (pt)
RO (1) RO114134B1 (pt)
RU (1) RU2109743C1 (pt)
TW (1) TW289754B (pt)
ZA (1) ZA948061B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
WO2001043697A2 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
CN100343258C (zh) * 2001-04-30 2007-10-17 美国拜尔公司 新的4－氨基－5,6－取代的噻吩并[2,3－d]嘧啶化合物
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
WO2006071274A2 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
EP1895995A2 (en) * 2005-05-13 2008-03-12 Alza Corporation Multilayer drug system for the delivery of galantamine
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
DK2137192T3 (da) 2008-04-14 2014-05-26 Neurodyn Life Sciences Inc Derivater af galantamin som prodrugs til behandling af humane hjernesygdomme
AU2010275431A1 (en) * 2009-07-23 2012-02-23 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof
US11219627B2 (en) * 2014-05-16 2022-01-11 Synaptec Development Llc Clearance of amyloid beta
EP4029867A1 (en) 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
ATE411026T1 (de) * 1987-05-04 2008-10-15 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
ATE183084T1 (de) 1991-05-14 1999-08-15 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
EP0649846A1 (en) 1995-04-26
ATE211474T1 (de) 2002-01-15
PT649846E (pt) 2002-06-28
NO943895D0 (no) 1994-10-14
NZ264682A (en) 1995-07-26
AU7581394A (en) 1995-05-04
RU94036745A (ru) 1996-12-10
JPH07188239A (ja) 1995-07-25
KR100227957B1 (ko) 1999-11-01
DK0649846T3 (da) 2002-04-15
IL111275A0 (en) 1994-12-29
DE69429570T2 (de) 2002-08-29
DE69429570D1 (de) 2002-02-07
CZ254594A3 (en) 1995-07-12
CA2118172C (en) 2000-01-04
IL111275A (en) 2003-01-12
CZ283731B6 (cs) 1998-06-17
PL305457A1 (en) 1995-04-18
US6316439B1 (en) 2001-11-13
RO114134B1 (ro) 1999-01-29
CA2118172A1 (en) 1995-04-16
AU696170B2 (en) 1998-09-03
TW289754B (pt) 1996-11-01
ES2170759T3 (es) 2002-08-16
CN1108657A (zh) 1995-09-20
NO943895L (no) 1995-04-18
CN1039910C (zh) 1998-09-23
FI108722B (fi) 2002-03-15
PL177549B1 (pl) 1999-12-31
NO307464B1 (no) 2000-04-10
RU2109743C1 (ru) 1998-04-27
FI944823A (fi) 1995-04-16
EG20726A (en) 1999-12-29
FI944823A0 (fi) 1994-10-13
KR950011445A (ko) 1995-05-15
JP2664343B2 (ja) 1997-10-15
EP0649846B1 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
ZA948061B (en) Galanthamine derivatives a process for their preparation and their use as medicaments
CA2333703A1 (en) Isothiazole derivatives useful as anticancer agents
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
HU906402D0 (en) Process for producing tricyclic carbapeneme derivatives an pharmaceutical preparatives containing these compounds as active substance
EP0437030A3 (en) Use of 4-substituted imidazoles for lowering intraocular pressure
ES8606282A1 (es) Un procedimiento de preparar derivados de acidos quinolin- ynaftiridin-carboxilicos
IL75115A0 (en) Beta-carboline-3-oxadiazolyl derivatives,process for the preparation thereof and pharmaceutical compositions containing the same
PL309874A1 (en) Novel derivatives of pyrrolocarbasol, method of obtaining them and pharmaceutical composition containing such derivatives
AU649882B2 (en) Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs, a process for their preparation and their use as medicaments
ZA932359B (en) 3-Aminochroman spiro compounds processes for preparing them and pharmaceutical compositions containing them
IL113780A (en) Glucopyranoside benzothiophenes process for their preparation and pharmaceutical compositions containing them
CS368890A3 (en) Aminooligohydroxy derivatives inhibiting effects of renin, process for their preparation and a pharmaceutical containing them
WO2000008006A3 (en) Piperidine and piperazine derivatives, process for their preparation and pharmaceutical compounds containing them
HUT45059A (en) Process for producing abeoergoline derivatives
AU657423B2 (en) Novel piperidine derivatives and process for preparation thereof
IL106934A (en) Heteroarenylpiperazines a process for their preparation and pharmaceutical compositions comprising them
MXPA99003849A (es) Derivados 9a, 11b-deshidro de 9-oxima-3-ceto-6-0-metileritromicina.